PureFunds ETFx HealthTech ETF IMED 深 滬
已收盤 10-08 16:00:00 美东时间
28.96
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 28.96
- 總市值 290.00万
- 52周最高 56.28
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 23.16
- 委 比 0.00%
- 總股本 10.01万
- 歷史最高 56.28
- 量 比 0
- 振 幅 0.00%
- 歷史最低 23.16
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Mendra Launches With $82M Series A To Acquire, Develop, Commercialize Therapeutics For High Unmet Need Rare Diseases
BRIEF-Mendra Launches With $82M Series A To Acquire, Develop, Commercialize Therapeutics For High Unmet Need Rare Diseases Jan 22 (Reuters) - MENDRA LAUNCHES WITH $82 MILLION SERIES A TO ACQUIRE, DEVELOP, AND COMMERCIALIZE THERAPEUTICS FOR HIGH UNMET NEED RARE DISEASES MENDRA: ROUND WAS CO-LED BY OR
01-22 20:09
BRIEF-Apimeds Pharmaceuticals Us Inc Says IPO Price Range Expected Between $4.00 And $5.00
Jan 29 (Reuters) - APIMEDS PHARMACEUTICALS US INC - IPO PRICE RANGE EXPECTED BETWEEN $4.00 AND $5.00 APIMEDS PHARMACEUTICALS US INC SEES IPO OF UP TO 4.5 MILLION SHARES OF COMMON STOCK Source text: [I...
2025-01-30 07:31
BRIEF-Humanetics Announces Positive Phase 2 COVID-19 Trial Results for Improved Pulmonary Function
Jan 22 (Reuters) - HUMANETICS CORPORATION: HUMANETICS CORPORATION ANNOUNCES POSITIVE PHASE 2 CLINICAL TRIAL RESULTS IN COVID-19 STUDY AIMED AT IMPROVING PULMONARY FUNCTION ((Reuters.Briefs@thomsonreut...
2025-01-23 01:58
BRIEF-Sionna Therapeutics Files For Initial Public Offering
Jan 17 (Reuters) - SIONNA THERAPEUTICS INC - FILES FOR INITIAL PUBLIC OFFERING SIONNA THERAPEUTICS INC - APPLIES TO LIST ON NASDAQ UNDER SYMBOL 'SION' SIONNA THERAPEUTICS INC SAYS ENTITIES AFFILIATED ...
2025-01-18 06:07
BRIEF-MiMedia Enters Into Debt Settlement Agreement
Jan 16 (Reuters) - MiMedia Holdings Inc MIM.V: MIMEDIA ENTERS INTO DEBT SETTLEMENT AGREEMENT Source text: ID:nCNWZSFVqa Further company coverage: MIM.V ((Reuters.Briefs@thomsonreuters.com;))
2025-01-16 21:18
BRIEF-Windward Bio Launches With $200 Million Series A Financing
Jan 10 (Reuters) - Windward Bio: WINDWARD BIO LAUNCHES WITH $200 MILLION SERIES A FINANCING TO DEVELOP PHASE 2-READY, LONG-ACTING ANTI-TSLP ANTIBODY WITH BEST-IN-CLASS POTENTIAL IN ASTHMA AND COPD WIN...
2025-01-10 22:09
BRIEF-FDA Proposes Updated Recommendations To Help Improve Performance Of Pulse Oximeters Across Skin Tones
Jan 6 (Reuters) - FDA PROPOSES UPDATED RECOMMENDATIONS TO HELP IMPROVE PERFORMANCE OF PULSE OXIMETERS ACROSS SKIN TONES FDA: UPDATED DRAFT RECOMMENDATIONS AIMED AT HELPING GENERATE A MORE REPRESENTATI...
2025-01-06 22:50
